2-Methylpropyl 4-(propan-2-yl)benzoate | 6315-03-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-Methylpropyl 4-(propan-2-yl)benzoate
• 英文别名: 2-methylpropyl 4-propan-2-ylbenzoate
• CAS: 6315-03-3
• 化学式: C₁₄H₂₀O₂
• 分子量: 220.31
• InChiKey: NSBLZOPMGZVJAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HIGHLY PHOTO-STABLE BIS-TRIAZOLE FLUOROPHORES
  申请人：NITTO DENKO CORPORATION

  公开号：US20180002337A1

  公开（公告）日：2018-01-04

  This disclosure is related to photo-stable chromophores which are useful in various applications. Chromophores disclosed herein include a bis-triazole core, two electron-donors at C-4 and C-8, and two groups derived from pentaerythritol (R═OR 5 ) or 1,1,1-tris(hydroxymethyl)methane (R═H) at N-2 and N-6. Such structures have been proven to have greater then five times higher photo-stability than their analogs with simpler alkyl groups at N-2 and N-6.

  这项披露涉及在各种应用中有用的光稳定的色团。这里披露的色团包括一个双三唑核心，C-4和C-8处的两个电子给体，以及N-2和N-6处源自对羟基甲基苯甲醇（R═OR5）或1,1,1-三(羟甲基)甲烷（R═H）的两个基团。这样的结构已被证明比其N-2和N-6处具有更简单烷基基团的类似物具有五倍以上的光稳定性。
• Highly photo-stable bis-triazole fluorophores
  申请人：NITTO DENKO CORPORATION

  公开号：US10005787B2

  公开（公告）日：2018-06-26

  This disclosure is related to photo-stable chromophores which are useful in various applications. Chromophores disclosed herein include a bis-triazole core, two electron-donors at C-4 and C-8, and two groups derived from pentaerythritol (R═OR5) or 1,1,1-tris(hydroxymethyl)methane (R═H) at N-2 and N-6. Such structures have been proven to have greater then five times higher photo-stability than their analogs with simpler alkyl groups at N-2 and N-6.

  本公开涉及在各种应用中有用的光稳定发色团。本文公开的发色团包括一个双三唑核心，C-4 和 C-8 处的两个电子供体，以及 N-2 和 N-6 处的两个来自季戊四醇（R═OR5）或 1,1,1-三（羟甲基）甲烷（R═H）的基团。事实证明，这种结构的光稳定性比 N-2 和 N-6 上含有较简单烷基的类似物高出五倍以上。
• Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof
  申请人：Whitehead Institute for Biomedical Research

  公开号：US11225469B2

  公开（公告）日：2022-01-18

  The present invention provides compounds of Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, pro-drugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I), (II) or (III) for treating diseases associated with the over-expression of phosphoglycerate dehydrogenase (PHGDH) in a subject, such as proliferative diseases (e.g., cancers (e.g., breast cancer, ER negative breast cancer, melanoma, cervical cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases). Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the activity of PHGDH or inhibit the serine biosynthetic pathway, or both.

  本发明提供了式(II)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同分异构体、立体异构体、同位素标记的衍生物、原药及其组合物。还提供了涉及式(I)、(II)或(III)化合物的方法和试剂盒，用于治疗与受试者体内磷酸甘油脱氢酶（PHGDH）过度表达有关的疾病，如增殖性疾病（如癌症（如乳腺癌、ER阴性乳腺癌、黑色素瘤、宫颈癌）、良性肿瘤、与血管生成有关的疾病、炎症性疾病、自身炎症性疾病和自身免疫性疾病）。使用本发明的化合物或组合物治疗增殖性疾病患者，可抑制 PHGDH 的活性或抑制丝氨酸生物合成途径，或两者兼而有之。
• INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF
  申请人：Whitehead Institute for Biomedical Research

  公开号：US20180105508A1

  公开（公告）日：2018-04-19

  The present invention provides compounds pounds of Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, pro-drugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I), (II) or (III) for treating diseases associated with the over-expression of phosphoglycerate dehydrogenase (PHGDH) in a subject, such as proliferative diseases (e.g., cancers (e.g., breast cancer, ER negative breast cancer, melanoma, cervical cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases). Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the activity of PHGDH or inhibit the serine biosynthetic pathway, or both.